Eli Lilly is the only megacap in the top Growth Score not linked to AI.

Its "AI" is next-gen obesity drugs.

Growth is backed by weight-loss pill Foundayo.

Peak sales forecast: $ 26-30B per year by end of decade, potentially the best-selling drug in pharma history.

The pill opens up the market to new patients who previously refused GLP-1s due to cost or fear of needles. $LLY